Generation Bio Co. (NASDAQ:GBIO) Given Average Recommendation of “Hold” by Analysts

Generation Bio Co. (NASDAQ:GBIO) has earned an average rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $8.00.

GBIO has been the subject of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of Generation Bio in a research note on Wednesday, April 10th. Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a research note on Thursday, March 7th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GBIO. SG Americas Securities LLC bought a new position in Generation Bio during the third quarter valued at about $51,000. TD Asset Management Inc boosted its stake in Generation Bio by 72.1% during the third quarter. TD Asset Management Inc now owns 406,598 shares of the company’s stock valued at $1,541,000 after buying an additional 170,343 shares in the last quarter. Kestra Private Wealth Services LLC bought a new position in Generation Bio during the fourth quarter valued at about $50,000. Los Angeles Capital Management LLC boosted its stake in Generation Bio by 315.6% during the fourth quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company’s stock valued at $455,000 after buying an additional 209,462 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new position in Generation Bio during the fourth quarter valued at about $49,000. Institutional investors own 95.22% of the company’s stock.

Generation Bio Price Performance

Shares of GBIO opened at $2.83 on Friday. The company has a market cap of $188.17 million, a P/E ratio of -1.44 and a beta of 2.78. The stock has a fifty day moving average price of $3.16 and a 200 day moving average price of $2.19. Generation Bio has a 12 month low of $0.86 and a 12 month high of $6.98.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.12). The company had revenue of $2.88 million during the quarter, compared to analysts’ expectations of $3.05 million. As a group, research analysts anticipate that Generation Bio will post -1.34 earnings per share for the current year.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.